Considerations in clinical trials of combination antifungal therapy

Clinical Infectious Diseases

Volumn 39, Issue SUPPL. 4, 2004, Pages

  Powers, John H ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ANTIFUNGAL PROPHYLAXIS; ARTICLE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFECTION PREVENTION; METHODOLOGY; MONOTHERAPY; MYCOSIS; NONHUMAN; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR;

ANTIFUNGAL AGENTS; CLINICAL TRIALS; DRUG COSTS; DRUG THERAPY, COMBINATION; DRUG TOXICITY; HUMANS; MYCOSES; PATIENT SELECTION; PREVENTIVE MEDICINE; RESEARCH DESIGN;

EID: 12844257412     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421962     Document Type: Article

References (40)

1. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301:126-31.
2. Codish SD, Tobias JS, Hannigan M. Combined amphotericin B - flucytosine therapy in Aspergillus pneumonia. JAMA 1979; 241:2418-9.
3. Ribner B, Keusch GT, Hanna BA, Perloff M. Combination amphotericin B - rifampin therapy for pulmonary aspergillosis in a leukemic patient. Chest 1976; 70:681-3.
4. George D, Kordick D, Miniter P, Patterson TF, Andriole VT. Combination therapy in experimental invasive aspergillosis. J Infect Dis 1993; 168:692-8.
5. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
6. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982; 97:496-503.
7. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 1995; 274:1706-13.
8. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48:693-715.
9. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540-6.
10. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003; 123:1503-11.
11. Waterer GW. Combination antibiotic therapy with macrolides in community-acquired pneumonia: more smoke but is there any fire? Chest 2003; 123:1328-9.
12. Powers JH, Cooper CK. Evaluating combination therapy in community-acquired pneumonia [letter]. Chest 2004; 125:353.
13. Mandell GL, Kaye D, Levison ME, Hook EW. Enterococcal endocarditis: an analysis of 38 patients observed at the New York Hospital-Cornell Medical Center. Arch Intern Med 1970; 125:258-64.
14. Lepper MH, Spies HW. Treatment of pneumococcic meningitis; results when penicillin was used alone compared with those when penicillin and streptomycin were used together, with and without hydrocortisone: alternate patient studies. AMA Arch Intern Med 1959; 104:253-9.
15. Ling J, Baird JK, Fryauff DJ, et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention cf Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 2002; 35:825-33.
16. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-50.
17. Dodds ES, Drew RH, Perfect JR. Antifungal pharmacodynamics: review of the literature and clinical applications. Pharmacotherapy 2000; 20:1335-55.
18. Pastel DA. Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination. Clin Pharm 1986; 5:719-36.
19. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-46.
20. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999; 44:263-73.
21. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36:1221-8.
22. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97:1025-32.
23. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98:292-9.
24. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995; 39:1907-12.
25. Powers JH. Counterpoint: alternative trial designs for antifungal drugs - time to talk. Clin Infect Dis 2001; 33:107-9.
26. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125:605-13.
27. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, eds. Clinical measurement in drug evaluation. New York: Wiley & Sons, 1995.
28. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-40.
29. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
30. Fleming TR. Surrogate markers in AIDS and cancer trials. Stat Med 1994; 13:1423-35.
31. Sande MA, Carpenter CC, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. JAMA 1993; 270:2583-9.
32. Johann-Liang R, Zalkikar J, Powers JH. Correlation between bacteriologic and clinical endpoints in trials of acute otitis media. Pediatr Infect Dis J 2003; 22:936-7.
33. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:1325-30.
34. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis: disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993; 17:103-9.
35. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11:99-109.
36. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: amulticenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
37. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-33.
38. Powers JH, Ross DB, Brittain E, Albrecht R, Goldberger MJ. The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents. Clin Infect Dis 2002; 34:879-81.
39. Voriconazole. Med Lett Drugs Ther 2002; 44:63-5.
40. Tukey JW. The future of data analysis. Annals of Mathematical Statistics 1962; 33:1-67.